You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Biogen Idec gains on new MS drug’s sales

Biogen targets autoimmune and neurodegenerative disorders and hemophilia.

Suzanne Kreiter/Globe Staff/File

Biogen targets autoimmune and neurodegenerative disorders and hemophilia.

Continue reading below

Biogen Idec Inc. shares climbed 4.9 percent to a record $223.98 before closing at $223.61, up
­4.7­ percent. The Weston company’s new multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis and Sanofi, Bloomberg News reported, suggesting the treatment may beat sales estimates for the year. Total­ prescriptions more than doubled during the third week of the launch to 730 from 332 the previous week, according to Wells Fargo & Co.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.